Potential and challenges of cross-border approaches to HTA
Wednesday 4 December, 2pm
We are very excited to welcome Prof Mike Drummond to present the final ISPOR NZ webinar for 2024, on the Potential and Challenges of Cross-Border Approaches to HTA.
Health technology assessment is mainly viewed as an activity pursued within a given jurisdiction, but there may be benefits from cross-border collaboration, such as pooling expertise and avoiding repetition in tasks, such as undertaking multiple systematic reviews of the same body of evidence. However, a cross-border approach raises several technical issues relating to the transferability of data and analysis from one setting to another, plus practical issues relating to the timing of reimbursement decisions in different jurisdictions and differences in willingness to pay.
In this presentation the potential and challenges of cross-border approaches will be discussed, based on previous research into the transferability of HTA/economic analyses, the experience of jurisdictions with pluralistic health care systems (eg where the responsibility for health care is devolved to regions with the country), and the new European Union regulation of HTA which seeks to provide assessments that will be used in all 27 member states.
The webinar will be held via Zoom at 2:00pm on Wednesday 4 December. To register, please complete the form on this page.
About the speaker
Michael Drummond, BSc, MCom, DPhil is Professor of Health Economics and former Director of the Centre for Health Economics at the University of York. His particular field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunization programmes, services for people with AIDS, eye health care and pharmaceuticals. He is the author of two major textbooks and more than 650 scientific papers, and has acted as a consultant to the World Health Organization and the European Union.
He has been President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research. In October 2010 he was made a member of the National Academy of Medicine in the USA. He has advised several governments on the assessment of health technologies and chaired one of the Guideline Review Panels for the National Institute for Health and Care Excellence (NICE) in the UK. He is the former Co-Editor-in-Chief of Value in Health and has been awarded 3 honorary doctorates, from City University (London), Erasmus University (Rotterdam) and the University of Lisbon
Comments